Ameriprise
ATOS icon

Ameriprise’s Atossa Therapeutics ATOS Stock Holding History

Ameriprise’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$498K Buy
258,234
+3,100
+1% +$14.1K ﹤0.01% 3664
2026
Q1 		$1.34M Buy
255,134
+2,397
+0.9% +$15.2K ﹤0.01% 3160
2025
Q4 		$2.24M Buy
252,737
+55,970
+28% +$708K ﹤0.01% 2933
2025
Q3 		$2.56M Sell
196,767
-1,447
-0.7% -$17.9K ﹤0.01% 2882
2025
Q2 		$2.47M Buy
+198,214
New +$2.37M ﹤0.01% 2829
2022
Q4 		– Sell
-734
Closed -$9K – 3961
2022
Q3 		$9K Sell
734
-8
-1% -$116 ﹤0.01% 3937
2022
Q2 		$12K Sell
742
-218
-23% -$3.44K ﹤0.01% 3861
2022
Q1 		$18K Buy
+960
New +$19.5K ﹤0.01% 3905
2021
Q4 		– Sell
-1,990
Closed -$97K – 3959
2021
Q3 		$97K Buy
1,990
+1,098
+123% +$63.9K ﹤0.01% 3780
2021
Q2 		$85K Buy
+892
New +$47.2K ﹤0.01% 3834

Other funds holding ATOS

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ameriprise's ATOS Position: Q2 2026 in Review

Ameriprise increased its Atossa Therapeutics (ATOS) stake by 1.2% in Q2 2026, buying an estimated $14.1K and bringing the position to 258,234 shares worth $498K. The position accounts for ﹤0.01% of the portfolio, ranked #3664.

Ameriprise first reported a position in ATOS in Q2 2021 and has held it in 10 quarters since. The position peaked at $2.56M in Q3 2025. 31 funds tracked by Wall St. Rank hold ATOS as of Q2 2026.

  • Ameriprise held 258,234 shares of Atossa Therapeutics worth $498K as of Q2 2026.
  • Ameriprise bought 3,100 Atossa Therapeutics shares in Q2 2026, an estimated $14.1K.
  • Atossa Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3664 holding.
  • Ameriprise first reported a position in Atossa Therapeutics in Q2 2021 and has held it in 10 quarters since.
  • Ameriprise's Atossa Therapeutics position peaked at $2.56M in Q3 2025.
  • 31 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.